hCAIX-IN-16 

hCAIX-IN-16 (Compound 12d) is hCA IX inhibitor, with K_{i values of 190.0 and 187.9 nM for hCA IX and hCA XII, respectively. hCAIX-IN-16 can arrest the cell cycle of breast cancer MDA-MB-468 in G0-G1 and S phase and induce apoptosis. hCAIX-IN-16 shows good broad-spectrum anticancer activity and can be used for cancer research^[1].}

hCAIX-IN-16 (3.99 μM; 24 h) arrests cell growth in G0-G1 and S phases in MDA-MB-468 cells^[1].
hCAIX-IN-16 (10 µM) inhibits the growth of 44 cancer cell lines with GI% ≥ 10% and shows GI% ≥ 50% against leukemia, (CCRF-CEM, RPMI-8226 and SR) and breast cancer cell lines (T-47D and MDA-MB-468)^[1].
hCAIX-IN-16 induces cell death by the apoptotic mechanism in MDA‑MB‑468 cells^[1].
Inhibits (under hypoxic conditions) MDA-MB-468 and CCRF-CM cells with IC₅₀s of 3.99 and 4.51 µM, respectively^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

436.49

C₂₀H₂₀N₈O₂S

2849348-38-3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zain-Alabdeen AI, et al. Synthesis and anticancer activity of new benzensulfonamides incorporating s-triazines as cyclic linkers for inhibition of carbonic anhydrase IX. Sci Rep. 2022 Oct 6;12(1):16756.  [Content Brief]